Anecdotally, Yarlagadda et al. [37] reported a successful attempt at personalized treatment in advanced CCA harboring ERBB2 amplification, as detected by ctDNA analysis; the patient was treated with a combination of anti-HER2 drugs, trastuzumab, and pertuzumab, and achieved rapid and sustained clinical benefit. Here, ERBB2 is linked to cholangiocarcinoma.